drugset / Trial / NCT05133323

A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

NCT05133323

Phase 2 Completed 237 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindPrevention

Summary

Researchers are trying to learn whether a drug called Lu AG09222 can help prevent migraine headaches for people who have not been helped by other treatments that are used to prevent migraines. People who join this trial have tried 2 to 4 other medications to prevent their migraines, but these medications have not helped them. When the trial is over, researchers will use this information to find out if the number of migraine days decreased more for the participants who got either dose of Lu AG09222 than for the participants who got the placebo.

Timeline

Start
2021-11-11
Primary completion
2023-01-19
Completion
2023-03-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AG09222 Monoclonal antibody 100 mg Intravenous
Subject Lu AG09222 Monoclonal antibody 750 mg Intravenous

Indications